Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Non-Current Assets (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Non-Current Assets over the past 15 years, most recently at $153.7 million for Q2 2025.

  • Quarterly results put Non-Current Assets at $153.7 million for Q2 2025, down 11.14% from a year ago — trailing twelve months through May 2025 was $653.3 million (down 3.2% YoY), and the annual figure for FY2025 was $153.7 million, down 11.14%.
  • Non-Current Assets for Q2 2025 was $153.7 million at Lifecore Biomedical, Inc. \De\, roughly flat from $153.5 million in the prior quarter.
  • Over the last five years, Non-Current Assets for LFCR hit a ceiling of $356.6 million in Q2 2021 and a floor of $153.5 million in Q1 2025.
  • Median Non-Current Assets over the past 5 years was $169.6 million (2023), compared with a mean of $199.6 million.
  • Biggest five-year swings in Non-Current Assets: surged 161.44% in 2021 and later crashed 55.68% in 2022.
  • Lifecore Biomedical, Inc. \De\'s Non-Current Assets stood at $270.8 million in 2021, then plummeted by 42.05% to $156.9 million in 2022, then grew by 7.78% to $169.1 million in 2023, then grew by 2.62% to $173.5 million in 2024, then decreased by 11.45% to $153.7 million in 2025.
  • The last three reported values for Non-Current Assets were $153.7 million (Q2 2025), $153.5 million (Q1 2025), and $173.5 million (Q4 2024) per Business Quant data.